70% of Wilmot lands purchased by Region of Waterloo
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
13 minutes ago
- CTV News
Single-game Canucks tickets on sale, and some games start at $250
The Vancouver Canucks disastrous 2024/2025 season didn't stop owners from raising ticket prices for 2025/2026. Single game tickets are now available for fans who signed up for priority access, and the two most coveted games have wallet-busting prices. The cheapest seats to the Montreal Canadiens game on Saturday, Oct. 25 are $247 with taxes and fees. The most expensive ones are $789. That's more than most face value floor seats for Taylor Swift's Vancouver concerts last year. Prices are similar for the Toronto Maple Leafs one-and-only visit to Rogers Arena on Saturday, Jan. 31, 2026. Tickets to the home opener against Calgary start at $155 for nose bleeds. The cheapest tickets for the 41 home games are for mid-week matches against less coveted teams like Anaheim and Buffalo. Fans can get in the building for $103 for those games. Ticket broker Kingsley Bailey says the team is pricing out parents who want to bring their kids to games. 'They're playing it the way that they want to play it, maximize the return as much as they can. And unfortunately, who gets hurt in this is the fan. These prices are really pricing out a family to be able to go to game,' said Bailey. In his post-season press conference in April, Canucks president of hockey operations Jim Rutherford acknowledged many fans are upset that the team would raise prices after missing the playoffs. 'I understand the frustration. I don't want to pay more for anything, none of us do,' said Rutherford on April 21. The Canucks say the higher prices reflect the $7 million jump in the NHL salary cap for this upcoming season. 'Another part is the building that we have, is investing money back into an older building,' added Rutherford. The Canucks are replacing all the seats at Rogers Arena this summer. The new seats have a higher backrest and cup holders. But Bailey says fans can't enjoy them if they can't afford to get in the door. 'Some fans will, but a lot won't. And we will probably see last-minute price drops,' said Bailey. That is possible with the Canucks dynamic pricing model. But Bailey is skeptical the drops will be significant. 'That dynamic pricing is a misnomer,' he said. 'Dynamic pricing means there's no ceiling and there's no floor. But obviously there's a floor. For the worst games on a Tuesday night in February when nobody wants to go, that should be a $20 ticket, but still, it's like $80.' While the team is offering three-game packs for a discount, right now fans can't buy single -game tickets for under $100. And those who want to see marquee players and match ups will pay a lot more. The Canucks will try to prove to their fans that it's worth it when the regular season gets underway on Oct. 9.
CTV News
13 minutes ago
- CTV News
Trump plans to put 100 per cent tariff on computer chips, semiconductors
Trump plans to put 100 per cent tariff on computer chips, semiconductors U.S. President Donald Trump said Wednesday that he will impose a 100 per cent tariff on computer chips and semiconductors.
Globe and Mail
17 minutes ago
- Globe and Mail
Novavax (NVAX) Profit Jumps on Milestone
Key Points Novavax posted a surprise profit in Q2 2025, reporting GAAP EPS of $0.62 compared to an expected loss of $0.04 per share. Revenue (GAAP) was $239 million, well above the analyst estimate of $152.61 million, but down 42.4% from the prior year. Results included a large one-time $175 million milestone from Sanofi, highlighting a shift toward partnership-led revenues and away from direct product sales. These 10 stocks could mint the next wave of millionaires › Novavax (NASDAQ:NVAX), known for its protein-based vaccine technology, released its second quarter fiscal 2025 results on August 6, 2025. The standout news was a return to profitability on a GAAP basis, driven by significant partnership milestone payments, most notably a $175 million payment linked to U.S. regulatory approval of its COVID-19 vaccine. Revenue (GAAP) reached $239 million, ahead of analyst expectations of $152.61 million, while diluted earnings per share (GAAP) came in at $0.62, well above the expected loss of $0.04. While the company beat expectations decisively, its business model is in transition, with product sales falling sharply and partnership revenues comprising the bulk of results this period. Metric Q2 2025 Q2 2025 Estimate Q2 2024 Y/Y Change EPS – Diluted $0.62 ($0.04) $0.99 (37.4 %) Revenue $239 million $152.61 million $415 million (42.4 %) Product Sales $11 million $23 million (52.2 %) Licensing, Royalties and Other Revenue $229 million $393 million (41.7 %) Net Income $107 million $162 million (33.9 %) Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Company Overview and Success Drivers Novavax is a biotechnology company specializing in the development of recombinant protein-based vaccines, including its COVID-19 shot and the adjuvant Matrix-M, which enhances immune responses. Its core offering, Nuvaxovid, is the only recombinant protein-based, non-messenger RNA (mRNA) COVID-19 vaccine currently available in the U.S. In recent quarters, Novavax has shifted its focus from building and running a direct sales operation to leveraging strategic partnerships and licensing its vaccine platform to larger pharmaceutical firms. The company's future success hinges on its technology platform, the ability to win significant regulatory approvals, and the effectiveness of its partners—such as Sanofi, Takeda, and others—in bringing products to market and generating milestone and royalty revenues. Quarter Highlights and Financial Shifts This period was marked by outsized partnership revenues and shrinking product sales. The $239 million revenue figure (GAAP), though ahead of expectations, was mainly due to a one-off $175 million milestone from Sanofi following U.S. full approval (Biologics License Application, or BLA) of Nuvaxovid. By contrast, product sales (GAAP) shrank to just $11 million, less than half the prior year, as Sanofi took over commercialization in major markets. Licensing, royalties, and other revenue of $229 million (GAAP) includes a $175 million milestone earned related to the Nuvaxovid BLA approval, the company reported. The new mix signals a decisive transition away from selling directly to customers and toward relying on major pharma partners to handle marketing and distribution. Additional partners such as Takeda (Japan), Serum Institute, and SK bioscience contributed non-negligible revenue as Novavax's Matrix-M adjuvant and related vaccine ingredients enter more global markets. Expenses dropped sharply, contributing to positive net income of $107 million (GAAP). Research and development (R&D) expenses for the second quarter of 2025 were $79 million, compared to $107 million in the same period in 2024. The decrease was primarily due to reduced expenditures related to COVID-19 vaccine development and the elimination of the associated commercial manufacturing network infrastructure. Selling, general, and administrative expense dropped 57%, reflecting the winding down of Novavax's own commercial activities as partners ramp up their roles. The company's cash and equivalents stood at $628 million as of Q2 2025, down 33.0% from December 2024, but are set to be boosted by expected milestone receipts, including the $175 million from Sanofi due in the third quarter. Working capital (GAAP) swung to a positive $530 million as of Q2 2025, up sharply from a negative position at the end of 2024, indicating improved liquidity and a stronger balance sheet thanks to partnership payments. Business Model, Product Families, and Partnership Strategy Novavax's foundation is its proprietary vaccine technology, which uses protein nanoparticles and the Matrix-M adjuvant to stimulate the immune system. This approach is an alternative to mRNA vaccines like those developed by Pfizer and Moderna. While used initially for COVID-19 (Nuvaxovid), the platform is now being applied to new areas, including malaria, influenza, respiratory syncytial virus (RSV), shingles, and even experimental cancer vaccines. The late-stage COVID-19-Influenza-Combination vaccine and standalone flu programs are being advanced with the intention to out-license or partner before further clinical development. The company has stated it does not intend to launch these vaccine candidates without a partner and will not make additional investments in the program until a partner is in place. (As of Q2 2025, the initial Phase 3 cohort was completed, and the company is seeking a partner to advance and fund all future clinical development, regulatory filing, and commercialization activities.) Novavax reported early positive immune response data in a 2,000-participant safety and immunogenicity study in Q2 2025, with T-cell responses described as "numerically higher than in the comparator Fluzone HD arm." Other parts of the pipeline remain preclinical or in early development, such as candidates targeting H5N1 flu and new projects in oncology and C. difficile. Most Notable Developments During the Quarter Novavax's most significant event was the U.S. FDA approval of Nuvaxovid, which unlocked the milestone payment from Sanofi. Transfers of marketing authorization to Sanofi for the U.S. and European Union (EU) markets are expected in the fourth quarter of 2025. Sanofi is scheduled to assume responsibility in the U.S. for the 2025-2026 COVID-19 vaccination season. An additional $50 million in milestones is anticipated upon the transfer of marketing authorizations, expected by the end of 2025. This reflects a larger strategic transition, with Novavax positioning itself as a technology provider and relying on stronger partners to drive commercial growth. Financial performance this quarter was shaped primarily by these deal structures. Licensing, royalties, and other revenue (GAAP) made up nearly the entire topline. Product sales (GAAP) almost halved, as Novavax effectively stands back in territories where partners now control commercialization. The composition of revenue is increasingly 'lumpy' and tied to specific partnership milestones rather than steady product demand, meaning quarterly results may remain volatile as new deals are struck or as partners hit regulatory and commercial hurdles. On the cost side, the company continued to cut expenditures. Both research and development and selling, general, and administrative costs saw major declines, largely attributed to wind-downs in internal commercialization infrastructure and tighter capital allocation. The net result was a substantial improvement in total stockholders' equity (GAAP), which swung from a large deficit at year-end to positive territory, underlining the financial impact of the partnership-driven shift. The company signaled that future profitability would depend on securing further milestone payments, royalties, and strict cost controls, all of which are closely linked to the performance and commercial success of its partners. Looking Ahead: Guidance and Watchpoints Management raised its FY2025 adjusted (non-GAAP) revenue guidance, now expecting $1.00 billion to $1.05 billion. Expense guidance for combined research and development and selling, general, and administrative was raised to $495 million–$545 million for full year 2025, higher than previously, to account for the cost of a postmarketing commitment study requested by the U.S. Food and Drug Administration. Sanofi is set to reimburse Novavax for approximately 70% of these study expenses, which are expected to occur during 2025 and 2026. There remains no clear revenue guidance for future royalties or sales from Sanofi's commercialization of Nuvaxovid or other new vaccine combinations that may be developed using Novavax's technology. Future performance will largely reflect the timing and success of partnership deals, regulatory progress in the pipeline, and the commercial appetite for protein-based vaccines, especially as the global COVID-19 vaccine market normalizes. Investors should watch for updates on new collaborations, further regulatory milestones, and data from pipeline programs, all of which could drive additional milestone revenue. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 4, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
